{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:24:48Z","timestamp":1791829488588,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.lungcan.2020.11.028","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:39:40Z","timestamp":1607081980000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid"],"prefix":"10.1016","volume":"152","author":[{"given":"Wang Chun","family":"Kwok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan Fong","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Yan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chung Man","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chi Leung","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Sau Man","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence Chi Chun","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lungcan.2020.11.028_bib0005","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.11.028_bib0010","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.028_bib0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.JTO.0000268672.57002.69","article-title":"Survival without common toxicity criteria grade 3\/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis","volume":"2","author":"Pujol","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.11.028_bib0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/17425255.2011.587411","article-title":"Pharmacokinetic evaluation of pemetrexed","volume":"7","author":"Sorensen","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.11.028_bib0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt197823168","article-title":"Effect of pleural effusion on high-dose methotrexate kinetics","volume":"23","author":"Evans","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.lungcan.2020.11.028_bib0030","first-page":"3487","article-title":"Effect of route of administration and effusions on methotrexate pharmacokinetics","volume":"34","author":"Wan","year":"1974","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2020.11.028_bib0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/03602537808993779","article-title":"Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion","volume":"8","author":"Chabner","year":"1978","journal-title":"Drug Metab. Rev."},{"issue":"18","key":"10.1016\/j.lungcan.2020.11.028_bib0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.028_bib0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.028_bib0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.028_bib0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","article-title":"The effect of malignant effusions on methotrexate disposition","volume":"50","author":"Li","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.028_bib0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.11.028_bib0065","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI107362","article-title":"Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues","volume":"52","author":"Chabner","year":"1973","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.028_bib0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","article-title":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial","volume":"102","author":"Joerger","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.028_bib0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00280-005-0077-5","article-title":"A semimechanistic-physiologic population pharmacokinetic\/pharmacodynamic model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.028_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","article-title":"Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.028_bib0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-014-2485-x","article-title":"Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients","volume":"74","author":"Honore","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.11.028_bib0090","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-09-3324","article-title":"Pemetrexed safety and pharmacokinetics in patients with third-space fluid","volume":"16","author":"Dickgreber","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"9699","key":"10.1016\/j.lungcan.2020.11.028_bib0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.028_bib0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.11.028_bib0105","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/JTO.0000000000000207","article-title":"Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study","volume":"9","author":"Gridelli","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.028_bib0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/03007995.2018.1547273","article-title":"Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting","volume":"35","author":"Winfree","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.lungcan.2020.11.028_bib0115","doi-asserted-by":"crossref","first-page":"e823","DOI":"10.1016\/j.cllc.2018.05.013","article-title":"Pemetrexed continuation maintenance phase 3 trials in Nonsquamous, non-small-Cell lung Cancer: focus on 2-Year overall survival and continuum of care","volume":"19","author":"Patel","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.028_bib0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40271-018-0327-3","article-title":"Treatment decisions for advanced non-squamous non-small cell lung Cancer: patient and physician perspectives on maintenance therapy","volume":"12","author":"McMullen","year":"2019","journal-title":"Patient."},{"issue":"1","key":"10.1016\/j.lungcan.2020.11.028_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.resinv.2018.09.003","article-title":"Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: a subgroup analysis of elderly patients","volume":"57","author":"Nogami","year":"2019","journal-title":"Respir. Investig."},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.028_bib0130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4143\/crt.2018.324","volume":"51","author":"Yoo","year":"2019","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.028_bib0135","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2020.11.028_bib0140","unstructured":"Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220307169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220307169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:43Z","timestamp":1759236283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220307169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"alternative-id":["S0169500220307169"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.028","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}